Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735650 | 0.75 | SMN1; SMN2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL882697 | 0.73 | SLC5A2 (0.37) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL9611996 | 0.68 | SLC5A2 (0.47) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1035551 | 0.66 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL22942125 | 0.66 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1035552 | 0.66 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1666220 | 0.66 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1035411 | 0.66 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14305460 | 0.63 | SLC5A2 (0.65) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14305459 | 0.61 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457918-A2 | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | Bristol-Myers Squibb Company (US) | 2012-05-30 | — | — | EP | disclosed |